For instance, BRAF/MEK inhibitors have shown significant efficacy in treating papillary craniopharyngiomas harboring BRAF-V600E mutations, while VEGF inhibitors like bevacizumab have demonstrated benefits in managing schwannomas and other highly vascularized tumors. This evidence concerns the gene BRAF and schwannoma.